Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.33 CAD | -4.35% | -2.94% | -15.38% |
04-25 | Microbix to Present New Lab Accreditation Program at European Congress on Clinical Microbiology | MT |
04-25 | Microbix Collaborator Introduces New Lab Accreditation Program | CI |
Valuation
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 17.56 | 21.24 | 62 | 51.23 | 30.76 | 33.05 | - | - |
Enterprise Value (EV) 1 | 17.56 | 21.24 | 62 | 51.23 | 30.76 | 33.05 | 33.05 | 33.05 |
P/E ratio | - | - | 22.5 x | 39.2 x | - | 16.5 x | 16.5 x | 8.25 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 2.57 x | 4.28 x | 3.66 x | 2.48 x | 1.78 x | 1.55 x | 1.15 x |
EV / Revenue | - | 2.57 x | 4.28 x | 3.66 x | 2.48 x | 1.78 x | 1.55 x | 1.15 x |
EV / EBITDA | - | -30.3 x | 14.1 x | 19.1 x | -26 x | 10.9 x | 8.78 x | 4.67 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 96,973 | 108,773 | 124,849 | 138,991 | 137,009 | 137,417 | - | - |
Reference price 2 | 0.2400 | 0.2600 | 0.6300 | 0.5100 | 0.3050 | 0.3300 | 0.3300 | 0.3300 |
Announcement Date | 20/12/19 | 18/12/20 | 23/12/21 | 22/12/22 | 21/12/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 8.274 | 14.48 | 14 | 12.42 | 18.59 | 21.32 | 28.77 |
EBITDA 1 | - | -0.7002 | 4.405 | 2.677 | -1.184 | 3.025 | 3.762 | 7.082 |
EBIT | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | 2.517 | 1.37 | - | - | - | - |
Net income | 0.0242 | - | 2.517 | 1.309 | - | - | - | - |
Net margin | - | - | 17.39% | 9.35% | - | - | - | - |
EPS 2 | - | - | 0.0280 | 0.0130 | - | 0.0200 | 0.0200 | 0.0400 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20/12/19 | 18/12/20 | 23/12/21 | 22/12/22 | 21/12/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: September | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 4.383 | 3.832 | 3.748 | 3.926 | 3.178 | 1.862 | 3.128 | 4.127 | 3.207 | 6.203 | 3.762 | 3.984 | 4.574 |
EBITDA 1 | 1.407 | 1.063 | 0.9177 | 0.8412 | 0.0251 | -0.7151 | 0.3154 | -0.2704 | -0.5109 | 2.178 | 0.074 | 0.221 | 0.516 |
EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | 0.6064 | 0.695 | 0.5633 | 0.5006 | - | -0.9669 | 0.0234 | - | - | - | - | - | - |
Net income | 0.6064 | 0.695 | 0.5633 | 0.5003 | - | -0.9669 | 0.0234 | - | - | - | - | - | - |
Net margin | 13.84% | 18.14% | 15.03% | 12.74% | - | -51.93% | 0.75% | - | - | - | - | - | - |
EPS | 0.006000 | 0.006000 | 0.005000 | 0.004000 | -0.003000 | -0.009000 | - | -0.006000 | 0.0140 | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 23/12/21 | 10/02/22 | 12/05/22 | 11/08/22 | 22/12/22 | 09/02/23 | 11/05/23 | 10/08/23 | 21/12/23 | 14/02/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 20/12/19 | 18/12/20 | 23/12/21 | 22/12/22 | 21/12/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.38% | 33.05M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- MBX Stock
- Financials Microbix Biosystems Inc.